- Home
- GCBC vs PHAT Comparison
GCBC vs PHAT Comparison
Compare GCBC & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GCBC
- PHAT
- Stock Information
- Founded
- GCBC 1889
- PHAT 2018
- Country
- GCBC United States
- PHAT United States
- Employees
- GCBC N/A
- PHAT N/A
- Industry
- GCBC Banks
- PHAT Biotechnology: Pharmaceutical Preparations
- Sector
- GCBC Finance
- PHAT Health Care
- Exchange
- GCBC Nasdaq
- PHAT Nasdaq
- Market Cap
- GCBC 452.9M
- PHAT 465.0M
- IPO Year
- GCBC 1998
- PHAT 2019
- Fundamental
- Price
- GCBC $27.19
- PHAT $5.67
- Analyst Decision
- GCBC
- PHAT Strong Buy
- Analyst Count
- GCBC 0
- PHAT 4
- Target Price
- GCBC N/A
- PHAT $23.00
- AVG Volume (30 Days)
- GCBC 20.6K
- PHAT 1.0M
- Earning Date
- GCBC 01-22-2025
- PHAT 03-06-2025
- Dividend Yield
- GCBC 1.32%
- PHAT N/A
- EPS Growth
- GCBC N/A
- PHAT N/A
- EPS
- GCBC 1.54
- PHAT N/A
- Revenue
- GCBC $65,848,000.00
- PHAT $26,270,000.00
- Revenue This Year
- GCBC N/A
- PHAT $7,453.23
- Revenue Next Year
- GCBC N/A
- PHAT $226.38
- P/E Ratio
- GCBC $17.66
- PHAT N/A
- Revenue Growth
- GCBC N/A
- PHAT N/A
- 52 Week Low
- GCBC $25.25
- PHAT $5.21
- 52 Week High
- GCBC $37.25
- PHAT $19.71
- Technical
- Relative Strength Index (RSI)
- GCBC 51.00
- PHAT 39.59
- Support Level
- GCBC $27.07
- PHAT $5.50
- Resistance Level
- GCBC $27.62
- PHAT $6.21
- Average True Range (ATR)
- GCBC 0.71
- PHAT 0.40
- MACD
- GCBC 0.16
- PHAT 0.07
- Stochastic Oscillator
- GCBC 77.95
- PHAT 38.69
About GCBC Greene County Bancorp Inc.
Greene County Bancorp Inc is a holding firm. Its primary business involves overseeing and directing the business of The Bank of Greene County and monitoring its cash position. Through its directly and indirectly owned subsidiaries, the company engages in attracting retail deposits, along with funds generated from operations and borrowings, predominantly in one to four-family residential mortgage loans, commercial real estate mortgage loans, consumer loans, home equity loans, and commercial business loans. It also serves local municipalities' banking needs and operates a real estate investment trust.
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.